Method of cancer treatment

Details Method of cancer treatment Method of cancer treatment

2007-04-17

2007-04-17

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C514S025000, C514S033000, C514S034000

Reexamination Certificate

active

11150461

ABSTRACT:
This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of(a) evaluating the subject to determine if the subject has relapsed or refractory cancer;(b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.

REFERENCES:
patent: 5811119 (1998-09-01), Mehta et al.
patent: 5821254 (1998-10-01), Sporn et al.
patent: 5874412 (1999-02-01), Priebe et al.
patent: 5902604 (1999-05-01), Zou et al.
patent: 6929802 (2005-08-01), Andreeff et al.
Perez-Soler, Cancer Research, vol. 50, pp. 4260-4266, 1990.
Zou, Cancer Research, vol. 54, pp. 1479-1484, 1984.
Perez-Soler, Cnacer Chemother. Pharmacol. vol. 34, pp. 109-118, 1994.□□.
Consoli, Blood, vol. 88, pp. 633-644, 1996□□Devita, Principles of Chemotherapy, ED., Philadelphia, 1993.
Acton et al., “Intensely potent morpholinyl anthracyclines,”J. Med. Chem., 27:638-645, 1984.
Barbieri et al., “Chemical and biological characterization of 4′-iodo-4′ deoxydoxorubicin,”Cancer Res., 47:4001-4006, 1987.
Chaudhary and Roninson, “Induction of multidrug resistance in human cells by transient exposure to difference chemotherapeutic drugs,”J. Natl. Cancer Inst., 85:632-639, 1993.
Consoli et al., The novel anthracycline annamycin is not affected by p-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cells lines,Blood, 88(2):633-644, 1996.
Dalton, “Overcoming the multidrug-resistant phenotype,”Principles and Practice of Oncology, 4thEd., 6:2655-2666, Philadelphia, 1993.
Den Boer et al., “Optimal immunocytochemical and flow cytometric detetection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia,”Leukemia, 11:1078-1085, 1997.
DeVita et al., “Principles of chemotherapy”,Principles and Practice of Oncology, 4thEd., Philadephia, 1993.
Gabizon et al., “Liposomes asin vivocarriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice,”Cancer Res., 42:4734-4739, 1982.
Ganapathi et al., “N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumors: cellular pharmacology and characterization of cross-resistancein vitroandin vivo,”Br. J. Cancer, 60:819-826, 1989.
Hermann et al., “Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation,”Cancer Res., 43:5427-5432, 1983.
Leith et al., “Correlation of multidrug resistance (MDRI) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR−/efflux+and MDRI+/efflux−cases,”Blood, 86:2329-2343, 1995.
Marie, “Phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice,”Leukemia, 11:1063-1066, 1997.
Mayhew et al., Inhibition of liver metastases of M 5076 tumor by liposome-entrapped adriamycin,Cancer Drug Delivery, 1:43-57, 1983.
Moscow and Cowan, “Multidrug resistance,”J. Natl. Cancer Inst., 80:14-20, 1989.
Perez-Soler and Priebe, “Anthracycline antibodies with high liposome entrapment; structural features and biological activity,”Cancer Res., 50:4260-4266, 1990.
Priebe et al., “Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity,”Anticancer Drugs, 4:37-48, 1993.
Rahman et al., Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes,Cancer Res., 46:2295-2299, 1986.
Zou et al., Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties, ABSTRACT,Cancer Res., 54:1479-1484, 1994.
Zou et al., “Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles,”Cancer Chemother. Pharmacol., 32:190-196, 1993.
Zou et al., “Quantitative analysis of the lipophilic doxorubicin analog annamycin in plasma and tissue samples by reverse-phase chromatography,”J. Pharm Sciences, 82:1151-1154, 1993.

Affiliated with

Also associated with

Rating

Method of cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of cancer treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3746989